All News
From the rising trend of royalty financing to other adaptive funding strategies, firms think outside the box in responding to unprecedented challenges.
Harpoon has several antibodies in its pipeline that are engineered to redirect a patient’s T cells to recognize and kill cancer cells.
The pharmaceutical giant will pay $28 a share to acquire Ambrx’s pipeline of ADCs, particularly its lead candidate for prostate cancer.
The Inflation Reduction Act, “march-in rights” to take back patents and M&A were among the issues discussed at a Sunday panel in San Francisco ahead of Monday’s start of the J.P. Morgan conference.
A day after inking an AI deal with Alphabet’s Isomorphic Labs, Novartis is back at it, acquiring Calypso Biotech and tying up with Shanghai Argo in two RNA-i-focused pacts.
Brand pharmas not only leverage ancillary patents but sometimes hide or misrepresent information to the U.S. patent office in order to extend market exclusivity and high prices.
The IPO window is starting to crack open this year, with Metagenomi and ArriVent making their offerings ahead of the J.P. Morgan Healthcare Conference.
BioSpace continues to bring you the latest news and industry developments from the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Stay tuned!
The multimillion-dollar collaboration will develop small molecule drugs against undisclosed targets.
The patient deaths were deemed unrelated to Vertex’s investigational islet cell therapy, but the study will be halted while regulatory authorities and an independent data monitoring committee review the findings.
The state must submit additional information about the drugs it intends to import before the first shipments are sent to the U.S.
After a topsy-turvy 2023, thousands of industry stakeholders will attend next week’s J.P. Morgan Healthcare Conference in San Francisco to answer a fundamental question: What will this year look like?
The therapeutic targets of many of our top startups are also reflected in recent big biopharma acquisitions and partnerships.
Targeting the red hot antibody-drug conjugate market, OnCusp Therapeutics is coming out of the gate with $100 million from investors such as Novo Holdings and OrbiMed.
In a major pivot, Allogene Therapeutics will no longer focus on two of its studies testing blood cancer therapy cema-cel in an effort to extend its financial runway into 2026.
While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.
Eli Lilly on Thursday announced the rollout of a new digital healthcare platform to streamline consumer access to its weight-loss drug Zepbound and other medications.
Once dormant due to a lack of commercial success and drug side effects, the radiopharmaceutical space is gaining momentum in the form of increased investment and scientific advances.
With recent scientific advances, milestone approvals and increased dealmaking, the future of treatment for neurological diseases looks brighter—but continued investment, collaboration and patient-focused efforts are key.
Under the deal disclosed Thursday in an SEC filing, bluebird bio doubled the number of covered U.S. patients for its sickle cell gene therapy to a cumulative total of around 200 million people.